ストックスクリーナーアプリを入手
4.36
0.68%
-0.03
Cingulate Inc (CING) 最新ニュース
Candel Therapeutics, Inc. (CADL) stock price, news, quote and history - Yahoo Finance Australia
Cingulate Warrants (CINGW) Hold Flat at $0.01 as Micro-Cap Warrant Sits at Its Pricing FloorEqual Weight ETF - siam.in
Cingulate Warrants (CINGW) Hold Flat at $0.01 as Micro-Cap Warrant Sits at Its Pricing FloorLeveraged ETF Flow - www.dars.gov.et
Cingulate Inc. (CING) Q2 2026 Earnings: Narrower-Than-Expected Loss Offers Modest Relief, but No Revenue Yet - dars.gov.et
Title: Cingulate Inc. (CING) Edges Lower to $5.09, Holding Above Key Support as Traders Eye $5.34 ResistanceEase of Movement - careplusvn.com
Title: Cingulate Inc. (CING) Edges Lower to $5.09, Holding Above Key Support as Traders Eye $5.34 ResistanceWave Truncation - siam.in
Title: Cingulate Inc. (CING) Edges Lower to $5.09, Holding Above Key Support as Traders Eye $5.34 ResistanceLeveraged ETF Flow - dars.gov.et
Title: Cingulate Inc. (CING) Edges Lower to $5.09, Holding Above Key Support as Traders Eye $5.34 ResistanceElliott Wave Entry - https://www.dars.gov.et/
Title: Cingulate Inc. (CING) Edges Lower to $5.09, Holding Above Key Support as Traders Eye $5.34 ResistanceTurnaround Stocks - dars.gov.et
CING Q2 2026 Earnings: Narrower Loss Delivers 29.4% EPS SurpriseRevenue Report - vinanet.vn
Caring Brands Inc. (Nasdaq: CABR) Completes Initial $4.6 Million Closing Under Ongoing $9 Million Private Placement - Yahoo Finance
Cingulate Inc. Warrants (CINGW) Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
Cingulate Inc. Warrants (CINGW) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Analysts Offer Insights on Healthcare Companies: Eloxx Pharmaceuticals (ELOX), Cingulate Inc (CING) and Agilon Health (AGL) - theglobeandmail.com
Cingulate (CING) Results Review: Reported EPS Misses Expectations; Latest Reaction: Shares Close 4.13% Higher for the Current SessionBasic EPS Analysis - vinanet.vn
Cingulate (CING) Results Review: Reported EPS Misses Expectations; Latest Reaction: Shares Close 4.13% Higher for the Current SessionFinancial Data - dars.gov.et
Cingulate (CING) Results Review: Reported EPS Misses Expectations; Latest Reaction: Shares Close 4.13% Higher for the Current SessionDividend Cut Risk - dars.gov.et
Zacks Research Has Bullish Outlook for Cingulate Q3 Earnings - MarketBeat
Ascendiant Capital Markets Cuts Cingulate (NASDAQ:CING) Price Target to $44.00 - MarketBeat
CINGULATE INC : ASCENDIANT CAPITAL MARKETS CUTS TARGET PRICE TO $44 FROM $52 - Bitget
Cingulate (CING) Results at a Glance: The EPS Result Is Below Expectation in Latest Trading; Market Reaction: The Market Price Moves 1.35% Higher in the Current UpdateCFO Commentary Report - dars.gov.et
Cingulate (CINGW) Levels: Finishes 26.88% Up at $0.01 at the Close; Trading Range: the Price Remains Bounded by the Supplied Support and Resistance at the CloseValue Area Low - vinanet.vn
Cingulate (CING) Quarterly Results: EPS Comes in Below Forecast; Closing Move: Shares Close 1.73% Higher in Latest TradingSurprise Factor Analysis - vinanet.vn
CING: Second Quarter Results - Yahoo Finance
Cingulate (CING) Results Breakdown: EPS Comes in Below Forecast at the Close; Market Read: The Share Price Sheds 0.19% in the Latest SessionEarnings Revision Upgrade - vinanet.vn
Cingulate CEO Dr. Shane J. Schaffer: Why a Child's ADHD Diagnosis Often Reveals ADHD in a Parent - inkl
Cingulate CEO Dr. Shane J. Schaffer: Why a Child's ADHD Diagnosis Often Reveals ADHD in a Parent - International Business Times
CING Q1 2026 Earnings: Wider-Than-Expected Loss of -$0.95 Per Share as Clinical-Stage Costs Persist - vinanet.vn
Cingulate (NASDAQ:CING) Upgraded by Wall Street Zen to "Sell" Rating - MarketBeat
Cingulate Stock Price Forecast. Should You Buy CING? - StockInvest.us
Cingulate (NASDAQ:CING) Posts Quarterly Earnings Results - MarketBeat
Form 8K Cingulate Inc For: 13 August By Investing.com - Investing.com Australia
Form 8K Cingulate Inc For: 13 August - Investing.com Nigeria
Form 8K Cingulate Inc For: 13 August By Investing.com - Investing.com Canada
Cingulate reports Q2 loss, plans FDA resubmission for ADHD drug - Investing.com Nigeria
Cingulate reports Q2 loss, plans FDA resubmission for ADHD drug By Investing.com - Investing.com Canada
Cingulate Inc. Q2 2026: Revenue $0 Net loss $5.87M — 10-Q Summary - TradingView
Cingulate reports Q2 loss, plans FDA resubmission for ADHD drug By Investing.com - Investing.com Australia
Form 8K Cingulate Inc For: 13 August By Investing.com - Investing.com India
Cingulate reports Q2 loss, plans FDA resubmission for ADHD drug - Investing.com
Cingulate reports Q2 loss, plans FDA resubmission for ADHD drug By Investing.com - Investing.com South Africa
Form 8K Cingulate Inc For: 13 August By Investing.com - Investing.com UK
Cingulate Reports $5.9 Million Second-Quarter Loss, $28.4 Million Cash - Quiver Quantitative
Cingulate Reports Q2 2026 Results: $28.4M Cash; Net Loss $5.9M for Quarter - TradingView
Cingulate reports Q2 loss, plans FDA resubmission for ADHD drug By Investing.com - Investing.com India
Cingulate reports Q2 loss, plans FDA resubmission for ADHD drug By Investing.com - Investing.com UK
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness - marketscreener.com
Cingulate Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Pagaya Technologies Warrants (PGYWW) Drop 7.02% to $0.03 as Trading Remains Pinned at Penny LevelETH Profile - careplusvn.com
Cingulate Inc. Warrants (CINGW) Rise 9.72% to $0.01 as Support and Resistance AlignTrend Following Picks - vinanet.vn
4.22%
大文字化:
|
ボリューム (24 時間):